Anti-activated state T cell antibody vaccine for preventing and/or treating immune correlated disease

An immune-related disease, activated state technology, applied in the field of anti-activated T cell antibody vaccines, can solve problems such as induction

Inactive Publication Date: 2009-04-08
PEKING UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] There are few studies on the role of antibodies after TCV immunization, but current studies have shown that after immunization with activated T cells, the host can produce antibodies against cell surface activation molecules, and BDA/IJ mice were i

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-activated state T cell antibody vaccine for preventing and/or treating immune correlated disease
  • Anti-activated state T cell antibody vaccine for preventing and/or treating immune correlated disease
  • Anti-activated state T cell antibody vaccine for preventing and/or treating immune correlated disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Embodiment 1, the mechanism of action of the vaccine for preventing and / or treating immune-related diseases of the present invention

[0080] 1. The target proteins recognized by anti-activated T cell antibodies are calreticulin (CRT), ERp57 and vimentin

[0081] In the process of studying the mechanisms of TCV-induced immune regulation, people have gained a better understanding of TCV-induced regulatory T cell responses, but little is known about TCV-induced specific humoral responses (ie, antibodies). In the present invention, the ovalbumin (OVA)-specific T cell line derived from BALB / c mice was used as a vaccine to immunize mice of the same strain, and it was found that TCV could induce a humoral immune response against activated T cells. This result reveals the existence of anti-T cell regulatory antibodies, lays the foundation for future research on regulatory anti-T cell antibodies (regulatory anti-T-cell Abs), and also proposes a new approach for the treatment of...

Embodiment 2

[0153] Embodiment 2, the immune prevention and immunotherapy effect of vaccine of the present invention

[0154] 1. Treatment of CIA

[0155] CFA was used to induce arthritis (AIA) in Lews rats, and after three immunizations, adoptive transfer of OVA immunized rat serum (OVA) (with OVA as the immunogen, the antiserum obtained by immunizing Lews rats with conventional methods), vimentin immunized rat serum (antiserum obtained by immunizing Lews rats with full-length vimentin by conventional methods), ERp57-1 immunized rat serum (antiserum obtained by immunizing Lews rats by conventional methods with ERp57-1 as immunogen), calreticulin -1 Immune rat serum (with calreticulin-1 as the immunogen, the antiserum obtained by immunizing Lews rats by conventional methods), RTV-S rat serum (except that the immunized animals are Lews rats, the preparation method is the same as that of RTV-S BALB / c mouse serum) and ATV-S rat serum (except that the immunized animal is Lews rat, the prepara...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an activated state resisting T cell antibody vaccine for preventing and/or treating immune-related diseases. The active component of the activated state resisting T cell antibody vaccine is a polyclonal antibody or a monoclonal antibody of an activated state resisting T lymphocyte cell and/or at least one of the following proteins or polypeptides: 1) a polypeptide which is obtained by losing a calreticulin protein and at least contains amino acid residues from the 21st to the 253th on the tail end of an amino acid of GenBank Accession Number AAH03453; 2) a polypeptide which is obtained by losing a ERp57 protein and at least contains the amino acid residues from the 27th to the 250th on the tail end of an amino acid of GenBank Accession Number P27773; 3) a vimentin protein; 4) the calreticulin protein; and 5) the ERp57 protein. The vaccine can be used for preventing and/or treating immune-related diseases of diabetes I, and/or systemic lupus erythematosus, and/or multiple sclerosis, and/or chronic hepatitis B, and/or rheumatoid arthritis, and/or experimental encephalomyelitis, and/or hypersensitivity diseases and the like.

Description

technical field [0001] The invention relates to an anti-activated T cell antibody vaccine for preventing and / or treating immune-related diseases. Background technique [0002] The immune system controls the immune response within an appropriate intensity through positive and negative feedback regulation through multiple channels. These include the regulation of antigens, the nervous system and the endocrine system, but the one that has received the most attention and is of critical importance is the regulation of regulatory T cells. The effective integration of this multi-channel regulation ensures the homeostasis of the immune system. [0003] T cells are central to the adaptive immune response and a major target of immune regulation. Many immune diseases arise from abnormalities in T cell activation or regulation. These diseases include autoimmune diseases, allergic diseases and the like. Autoimmune diseases are a class of frequently occurring diseases that seriously e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395A61P1/16A61P3/10A61P17/00A61P19/02A61P29/00A61P31/20A61P37/02A61P37/08
Inventor 高晓明仲昭岩许文洪超邱翔张岩
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap